Recent Research

Question 1

Anaemia and Kidney Disease

Answer 1

High haemoglobin levels were not beneficial based on the early trials with ESAs (erythropoietin stimulating agents).

Utilisation of a more proactive approach with intravenous iron could be beneficial

Excitement around HIF-PHI agents represents potentially new horizons

Question 2

ANCA Vasculitis:

Answer 2

IV cyclophosphamide, Oral cyclophosphamide or rituximab are all effective agents but they come with significant side effects

Plasma exchange should no longer be standard treatment

Lower dose steroids are as effective as high dose steroids

Question 3

IgA Nephropathy:

Answer 3

Supportive therapy

Reduce Proteinuria (ACE Inhibition) and good BP control is the main stay of treatment of IgA nephropathy
Immunosuppression did not improve the outcome

But had more side effects

Question 4

SGLT2 inhibitors:

Answer 4

This is potentially going to be the most significant new drug for patients with renal impairment, possibly the most significant since ACE inhibitors were discovered.

The SGLT2 drug reduced by 39% the primary endpoint of worsening kidney function (more than 50% sustained decline in estimated glomerular filtration rate [eGFR] or onset of end-stage kidney disease) or death due to kidney disease or cardiovascular disease.